Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724523 | 0.80 | PIK3CD (0.33) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL15724522 | 0.80 | PIK3CD (0.33) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL15171100 | 0.78 | HTR2A (0.38) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL15155901 | 0.78 | HTR2A (0.38) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL18677838 | 0.78 | PIK3CD (0.36) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL15156369 | 0.78 | HTR2A (0.38) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL15156084 | 0.78 | HTR2A (0.38) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL15709095 | 0.78 | HTR2A (0.38) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL15156366 | 0.78 | HTR2A (0.38) | PIK3CDKDM4ERAB9ALMNAGAA | |
| SCHEMBL12326039 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | WEE1, WEE2, CYP4F11 | PIK3CD 1091/4885KDM4E 3971/4885RAB9A 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.